Nutrition, 32, 409417
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al
Here is how GLP-1 options compare, according to clinical trials: Daily oral semaglutide (Wegovy): Average weight loss of 13.6 percent of body weight after about 15 months of treatment, compared with 2.2 percent in a placebo group Average weight loss of 11.2 percent of body weight after 72 weeks of treatment, compared with 2.1 percent in the placebo group
Methodological Quality and Risk of Bias Assessment We used the Cochrane Risk of Bias 2 (RoB 2) tool (crossover extension where applicable) for assessing the risk of bias to evaluate the methodological quality of RCTs
Like the A1C data presented above, weight loss was similar with 20 mg and 40 mg oral semaglutide when compared with the injectable semaglutide group